Korro Bio’s (KRRO) lead asset KRRO-110 failing to produce protective levels of corrected protein in a Phase 1/2 AATD trial, leading to its discontinuation, “clearly validated” Wave Life Sciences’ (WVE) approach and strengthened its competitive position, Jefferies analyst Roger Song tells investors. Korro announced its focus on developing a new AATD editor that will use GalNAc delivery, as is the case for WVE-006, notes the analyst, who has a Buy rating and $26 price target on Wave shares.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WVE:
- Wave Life Sciences: Advancements in RNA Medicines Strengthen Buy Rating
- Wave Life Sciences price target lowered to $16 from $18 at Wells Fargo
- Wave Life Sciences Advances RNA Therapies Amid Financial Progress
- Wave Life Sciences’ Earnings Call Highlights Clinical and Financial Progress
- Wave Life Sciences: Promising Data, Robust Pipeline, and Strong Financial Position Justify Buy Rating